Titre : | Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs |
Titre traduit : | (Rapport sur l'évaluation du risque lié à la consommation de PMMA dans le cadre de l'action commune sur les nouvelles drogues de synthèse) |
Type de document : | Rapport |
Editeur : | Lisbon : OEDT / EMCDDA, 2003 |
Collection : | Risk assessments, ISSN 1725-4493, num. n°5 |
ISBN/ISSN/EAN : | 978-92-9168-137-7 |
Format : | 122 p. / fig. ; tabl. |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés DROGUES DE SYNTHESE ; PHARMACOLOGIE ; NEUROBIOLOGIE ; MORTALITE ; EVALUATION ; FACTEUR DE RISQUE ; EPIDEMIOLOGIE ; SOCIOLOGIE ; CRIMINOLOGIE ; SURVEILLANCE EPIDEMIOLOGIQUE ; INTOXICATION ; TYPE D'USAGE ; PROHIBITION |
Résumé : |
ENGLISH :
Unlike ketamine and GHB, but similar to MBDB and 4-MTA, PMMA is one of the numerous "new synthetic drugs" with no legitimate therapeutic use that are described in Shulgin's Pihkal (Shulgin and Shulgin, 1991). PMMA is a structural hybrid of PMA (para-methoxyamphetamine) and methamphetamine and, although chemically analogous to MDMA, it has one oxygen atom removed. Thus it lacks the important methylenedioxy group present in MDMA. An overview of the scientific literature on the pharmacology and toxicology of PMMA in animals as well as on the human pharmacology, clinical experience and psychological risks of PMMA use was compiled by Professor Hans Rommelspacher from the Free University of Berlin in Germany. This overview was extended by a thorough review, conducted by Europol and the EMCDDA in association with the various Reitox national focal points, of the pharmacotoxicological, sociological and criminological information available on PMMA. The main difficulty encountered by experts was the relatively small amount of data existing in the literature for PMMA compared with that available for PMA. However, since both products occur in association in "ecstasy"-like tablets and present similar pharmacological characteristics, experts agreed to extrapolate some of the data obtained for PMA to PMMA. A preparatory technical expert meeting with members of the subcommittee for risk assessment was first held on 8 October 2001. Then, members of the Scientific Committee of the EMCDDA plus experts nominated by the Member States and representatives of the European Commission, of Europol and of the EMEA met in Lisbon on 29 October 2001 to discuss the health and social risks of PMMA as well as the possible consequences of its prohibition. The risk assessment report on PMMA was adopted by this assembly that same day. (Extract of the publication) |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 83 |
Affiliation : | Portugal |
Numéro Toxibase : | 1300536 |
Centre Emetteur : | 13 OFDT |
Cote : | OEDT-9.7 |
Lien : | http://www.emcdda.europa.eu/html.cfm/index33349EN.html |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Documents numériques (1)
EMCDDA_Risk5_PMMA_2003.pdf Adobe Acrobat PDF |
Accueil